Todos Medical Announces All 31 Patients Enrolled t

Todos Medical Announces All 31 Patients Enrolled to Date in Tollovir® Phase 2 Clinical Trial in Hospitalized COVID-19 Patients Have Completed Study Participation

Dr. Jules Mitchel now leading preparation for data lock and statistical analysisBusiness update call Today at 4:30PM EST

New York, NY, and Tel Aviv, ISRAEL, Dec. 02, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, together with its 3CL biology-focused joint venture partner NLC Pharma, today announced that all 31 patients enrolled to date in Tollovir® Phase 2 clinical trial in hospitalized COVID-19 patients have completed study participation and the data are now being entered into the database for analysis. Dr. Jules Mitchel, a strategic advisor retained by Todos to assist with the analysis, is now leading preparation for data lock and statistical analysis. The Company expects data analysis to be completed in December 2021.

The management team of Todos Medical, including Mr. Gerald E. Commissiong, President and Chief Executive Officer, will host a conference call today, December 2nd at 4:30 p.m. EST to discuss the Company’s business progress in 2021 and provide a strategic outlook for the future.

The call information is as follows:

·       Date:  December 2, 2021

·       Time:  4:30 p.m. Eastern Standard Time

·       Direct Dial-in number: (669) 900-6833

·       Meeting ID: 94945983568

·       Passcode: 167897
https://investor.todosmedical.com/news-events...to-date-in